Valproic Acid and Divalproex in Mood Disorders

Valproic acid is a branched short-chain fatty acid first developed as an antiseizure drug and later established as a mood stabilizer used chiefly for acute mania. Divalproex sodium (valproate semisodium) is a stable coordination compound of valproic acid and sodium valproate that dissociates to valproate in the gut; it is a common formulation used in psychiatry. The agent has a broad and incompletely defined pharmacology spanning ion channels, GABAergic transmission, and gene expression.

Definition

Valproic acid (valproate) is a branched short-chain fatty-acid anticonvulsant used as a mood stabilizer, particularly for acute mania; divalproex sodium is a 1:1 coordination complex of valproic acid and sodium valproate that delivers valproate after dissociation.

Scope

This entry covers valproate's pharmacology, the relationship between valproic acid and divalproex, the principal mechanistic hypotheses (effects on sodium channels, GABA, and chromatin/gene expression), and the trial and guideline evidence for its antimanic role. It is a pharmacological reference and does not provide dosing or safety counseling.

Core questions

• How does divalproex differ from valproic acid and sodium valproate?
• Through which mechanisms is valproate thought to stabilize mood?
• What is the evidence for valproate in acute mania versus maintenance?
• Why are valproate's molecular targets described as broad and incompletely defined?

Key concepts

• Branched short-chain fatty-acid structure
• Divalproex (valproate semisodium) formulation
• GABAergic enhancement
• Voltage-gated sodium-channel effects
• Histone deacetylase inhibition
• Hepatic metabolism and drug interactions
• Teratogenic potential

Key theories

Multimodal anticonvulsant mechanism of valproate

Valproate is proposed to act through several mechanisms, including enhancement of GABAergic transmission, attenuation of voltage-gated sodium-channel firing, and effects on neurotransmitter metabolism, without a single dominant target being established.

Histone deacetylase inhibition and gene-expression hypothesis

Valproate inhibits histone deacetylases and alters gene expression, an effect proposed to contribute to neurotrophic and neuroprotective actions relevant to its mood-stabilizing and broader therapeutic potential.

Mechanisms

Valproate's pharmacology is broad and not reducible to one target. Reviews of its basic pharmacology describe enhancement of GABAergic inhibitory transmission, reduction of high-frequency neuronal firing through effects on voltage-gated sodium channels, and influences on the metabolism of excitatory and inhibitory amino acids (Loscher 2002). Beyond classical anticonvulsant targets, valproate inhibits histone deacetylases and modulates intracellular signaling and gene expression, effects that have been linked to neurotrophic and neuroprotective actions and proposed as relevant to mood stabilization (Chiu 2013). Divalproex is a delivery formulation; once dissociated, the active moiety is valproate.

Clinical relevance

Valproate is positioned in guidelines as an option for acute mania and, in some settings, maintenance of bipolar disorder, and a landmark randomized trial established its antimanic efficacy relative to placebo (Bowden 1994; Yatham 2018). Reviews note that the agent has notable safety considerations, including teratogenicity, that shape its place in therapy (Loscher 2002). This entry describes how the drug works and is studied and is not a basis for individual treatment decisions.

Evidence & guidelines

The Bowden (1994) randomized, placebo-controlled trial demonstrated efficacy of divalproex in acute mania compared with placebo, with lithium as an active comparator, and contemporary guidelines incorporate valproate among recommended antimanic agents (Bowden 1994; Yatham 2018).

History

Valproic acid's anticonvulsant activity was discovered serendipitously in the 1960s when it was used as a solvent, and it became a mainstay antiseizure drug before its mood-stabilizing properties were recognized. The divalproex formulation and randomized trials such as Bowden (1994) consolidated its role in acute mania, and later mechanistic work extended interest to its epigenetic and neuroprotective effects (Bowden 1994; Chiu 2013).

Debates

Which of valproate's many actions account for its mood-stabilizing effect?

Valproate engages GABAergic, ion-channel, and epigenetic mechanisms, and it remains unresolved which of these, alone or in combination, underlies its clinical antimanic and prophylactic effects.

Key figures

• Charles Bowden
• Wolfgang Loscher
• De-Maw Chuang

Seminal works

• bowden-1994
• loscher-2002
• chiu-2013

Frequently asked questions

What is the difference between valproic acid, sodium valproate, and divalproex?

They are related forms delivering the same active valproate ion: valproic acid is the free acid, sodium valproate is its sodium salt, and divalproex sodium is a 1:1 coordination compound of the two that dissociates to valproate after administration.

Is valproate mainly used for mania or for depression in bipolar disorder?

The strongest evidence supports valproate for acute mania; its role in the depressive pole and in maintenance is more limited, as reflected in treatment guidelines.